Market Cap
US$56.2b
Last Updated
2021/06/23 02:53 UTC
Data Sources
Company Financials +
Executive Summary
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. More Details
Rewards
Risk Analysis
Snowflake Analysis
Undervalued with solid track record.
Similar Companies
Share Price & News
How has Humana's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HUM is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: HUM's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
2.6%
HUM
0.03%
US Healthcare
-0.1%
US Market
1 Year Return
14.1%
HUM
35.1%
US Healthcare
39.0%
US Market
Return vs Industry: HUM underperformed the US Healthcare industry which returned 35.1% over the past year.
Return vs Market: HUM underperformed the US Market which returned 39% over the past year.
Shareholder returns
| HUM | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.6% | 0.03% | -0.1% |
| 30 Day | -2.3% | -2.4% | 2.6% |
| 90 Day | 5.1% | 7.7% | 8.0% |
| 1 Year | 14.9%14.1% | 36.8%35.1% | 41.2%39.0% |
| 3 Year | 50.0%46.8% | 51.2%44.9% | 62.4%52.3% |
| 5 Year | 146.2%138.2% | 105.3%90.1% | 132.3%106.2% |
Long-Term Price Volatility Vs. Market
How volatile is Humana's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Humana (NYSE:HUM) Is Investing Its Capital With Increasing Efficiency1 week ago | Simply Wall St
Shareholders Are Thrilled That The Humana (NYSE:HUM) Share Price Increased 128%3 weeks ago | Simply Wall St
Does Humana (NYSE:HUM) Deserve A Spot On Your Watchlist?Valuation
Is Humana undervalued compared to its fair value and its price relative to the market?
38.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HUM ($435.73) is trading below our estimate of fair value ($706.11)
Significantly Below Fair Value: HUM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HUM is good value based on its PE Ratio (15.4x) compared to the US Healthcare industry average (20.5x).
PE vs Market: HUM is good value based on its PE Ratio (15.4x) compared to the US market (19.2x).
Price to Earnings Growth Ratio
PEG Ratio: HUM is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: HUM is good value based on its PB Ratio (4x) compared to the US Healthcare industry average (4.1x).
Future Growth
How is Humana forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
8.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HUM's forecast earnings growth (8.7% per year) is above the savings rate (2%).
Earnings vs Market: HUM's earnings (8.7% per year) are forecast to grow slower than the US market (15.6% per year).
High Growth Earnings: HUM's earnings are forecast to grow, but not significantly.
Revenue vs Market: HUM's revenue (9% per year) is forecast to grow slower than the US market (9.4% per year).
High Growth Revenue: HUM's revenue (9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HUM's Return on Equity is forecast to be low in 3 years time (18.9%).
Past Performance
How has Humana performed over the past 5 years?
26.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HUM has high quality earnings.
Growing Profit Margin: HUM's current net profit margins (4.7%) are higher than last year (3.9%).
Past Earnings Growth Analysis
Earnings Trend: HUM's earnings have grown significantly by 26% per year over the past 5 years.
Accelerating Growth: HUM's earnings growth over the past year (42.4%) exceeds its 5-year average (26% per year).
Earnings vs Industry: HUM earnings growth over the past year (42.4%) underperformed the Healthcare industry 59.7%.
Return on Equity
High ROE: HUM's Return on Equity (26.2%) is considered high.
Financial Health
How is Humana's financial position?
Financial Position Analysis
Short Term Liabilities: HUM's short term assets ($25.5B) exceed its short term liabilities ($15.3B).
Long Term Liabilities: HUM's short term assets ($25.5B) exceed its long term liabilities ($7.9B).
Debt to Equity History and Analysis
Debt Level: HUM's debt to equity ratio (50.2%) is considered high.
Reducing Debt: HUM's debt to equity ratio has increased from 41.3% to 50.2% over the past 5 years.
Debt Coverage: HUM's debt is well covered by operating cash flow (60.7%).
Interest Coverage: HUM's interest payments on its debt are well covered by EBIT (17.6x coverage).
Balance Sheet
Dividend
What is Humana current dividend yield, its reliability and sustainability?
0.64%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: HUM's dividend (0.64%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.29%).
High Dividend: HUM's dividend (0.64%) is low compared to the top 25% of dividend payers in the US market (3.45%).
Stability and Growth of Payments
Stable Dividend: HUM is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: HUM is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: HUM is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HUM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Bruce Broussard (58 yo)
8.42yrs
Tenure
US$16,489,639
Compensation
Mr. Bruce Dale Broussard serves as the Member of Advisory Board of HealthQuest Capital. Mr. Bruce serves as the President and chief Executive Officer at Humana Insurance Company of Kentucky. Mr. Bruce serv...
CEO Compensation Analysis
Compensation vs Market: Bruce's total compensation ($USD16.49M) is above average for companies of similar size in the US market ($USD11.27M).
Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: HUM's management team is considered experienced (2.5 years average tenure).
Board Members
Experienced Board: HUM's board of directors are considered experienced (7.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HUM insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Humana Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Humana Inc.
- Ticker: HUM
- Exchange: NYSE
- Founded: 1964
- Industry: Managed Health Care
- Sector: Healthcare
- Market Cap: US$56.215b
- Shares outstanding: 129.01m
- Website: https://www.humana.com
Number of Employees
Location
- Humana Inc.
- Humana Building
- 500 West Main Street
- Louisville
- Kentucky
- 40202
- United States
Listings
Biography
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/06/23 02:53 |
| End of Day Share Price | 2021/06/22 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.